Achieve Life Sciences (NASDAQ:ACHV) used its first-quarter 2026 earnings call to outline a transition period marked by new leadership, a major financing, manufacturing changes tied to its cytisinicline regulatory timeline and preparations for a potential commercial launch in 2027.
Dr. Andrew Goldberg, Achieve’s new chief executive officer, said he joined the company at “an important time” as it works to develop cytisinicline for smoking cessation and vaping cessation. Goldberg said nearly 50 million adults in the United States use nicotine, including approximately 25 million smokers and 18 million people who vape, and said current treatment options leave many patients unable to quit.
